Ardea Biosciences Secures $8 Million Growth Capital Loan
November 13 2008 - 8:30AM
Business Wire
Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that it
entered into an $8.0 million growth capital loan agreement with
Oxford Finance Corporation and Silicon Valley Bank. Among its
terms, the loan bears interest at 12% per annum over an approximate
3 year period and contains no financial covenants. In connection
with the loan, Ardea issued warrants to the lenders entitling them
to purchase up to approximately 56,000 shares of common stock over
a seven year period. �We are pleased to have closed this financing
under very challenging market conditions on favorable terms,�
commented Barry D. Quart, PharmD, Ardea�s president and chief
executive officer. �The proceeds from this loan, together with our
existing cash reserves, provide greater flexibility in ongoing
partnering discussions and allow us to fund operations into the
second half of 2009.� �Ardea Biosciences is focused on treatments
for some of our most life-threatening and debilitating diseases,
including HIV, gout and cancer,� said J. Alden Philbrick, president
and chief executive officer of Oxford Finance Corporation. �Oxford
and Silicon Valley Bank appreciate the opportunity to provide
capital to further the development of Ardea�s exciting pipeline
candidates.� About Ardea Biosciences, Inc. Ardea Biosciences, Inc.,
of San Diego, California, is a biotechnology company focused on the
discovery and development of small-molecule therapeutics for the
treatment of HIV, gout, cancer and inflammatory diseases. We have
five product candidates in clinical trials and others in
preclinical development and discovery. Our most advanced product
candidate is RDEA806, a non-nucleoside reverse transcriptase
inhibitor (NNRTI), which has successfully completed a Phase 2a
study for the treatment of patients with HIV. We have evaluated our
second-generation NNRTI for the treatment of HIV, RDEA427, in a
human micro-dose pharmacokinetic study and have selected it for
clinical development based on a plasma half-life of greater than 40
hours. RDEA594, our lead product candidate for the treatment of
hyperuricemia and gout, is being evaluated in a Phase 1 clinical
trial. We are evaluating our lead MEK inhibitor, RDEA119, in a
Phase 1/2 study in combination with sorafenib (Nexavar�, Onyx
Pharmaceuticals, Bayer HealthCare) and as a single agent in a Phase
1 study, both in advanced cancer patients, and have completed a
Phase 1 study in normal healthy volunteers as a precursor to trials
in patients with inflammatory diseases. Lastly, we have evaluated
our second-generation MEK inhibitor for the treatment of cancer and
inflammatory diseases, RDEA436, in a human micro-dose
pharmacokinetic study and have selected it for clinical
development. About Oxford Finance Corporation Oxford Finance
Corporation, a subsidiary of Sumitomo Corporation, is a specialty
finance firm providing senior secured loans to public and private
life science companies worldwide. For over 20 years, Oxford has
delivered flexible financing solutions to its clients, enabling
these companies to maximize their equity by leveraging their
assets. In recent years, Oxford has originated over $1 billion in
loans, with lines of credit ranging from $500 thousand to $30
million. Oxford is headquartered in Alexandria, Virginia, with
additional offices in California and Massachusetts. For more
information, visit www.oxfordfinance.com. About Silicon Valley Bank
Silicon Valley Bank (SVB) is the premier commercial bank for
emerging, growth and mature companies in the technology, life
science, venture capital/private equity and premium wine
industries. SVB provides a comprehensive suite of financing
solutions, treasury management, corporate investment and
international banking services to its clients worldwide. Through
its focus on specialized markets and extensive knowledge of the
people and business issues driving them, Silicon Valley Bank
provides a level of service and partnership that measurably impacts
its clients� success. Founded in 1983 and headquartered in Santa
Clara, California, the company serves clients around the world
through 27 U.S. offices and international operations in China,
India, Israel and the United Kingdom. Silicon Valley Bank is a
member of global financial services firm SVB Financial Group, with
SVB Analytics, SVB Capital, SVB Global and SVB Private Client
Services. More information on the company can be found at
www.svb.com. Statements contained in this press release regarding
matters that are not historical facts are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
our plans and goals, the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other
compounds, the timing and results of our preclinical, clinical and
other studies and our financial performance. Risks that contribute
to the uncertain nature of the forward-looking statements include
risks related to the outcome of preclinical and clinical studies,
risks related to regulatory approvals, delays in commencement of
preclinical and clinical studies, costs associated with our drug
discovery and development programs, and risks related to the
outcome of our business development activities. These and other
risks and uncertainties are described more fully in our most
recently filed SEC documents, including our Annual Report on Form
10-K and our Quarterly Reports on Form 10-Q, under the headings
"Risk Factors." All forward-looking statements contained in this
press release speak only as of the date on which they were made. We
undertake no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they
were made.
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Oct 2023 to Oct 2024